Bucindolol

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Bucindolol
Bucindolol.png
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
ECHA InfoCard 100.114.291 Edit this at Wikidata
Chemical and physical data
Formula C22H25N3O2
Molar mass 363.45 g/mol

Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[1][3]

See also[edit]

References[edit]

  1. ^ a b "formularyjournal.modernmedicine.com".
  2. ^ Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi:10.1159/000028179. PMID 9467185.
  3. ^ "FDA rejects bucindolol and questions trial integrity « CardioBrief".